CMAHP: A Potential Drug Target for Various Diseases (G8418)

Target Name: CMAHP

NCBI ID: G8418

Other Name(s): CSAH | cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene | Cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene, transcript variant 1 | CMAHP variant 1 | CMAH

CMAHP: A Potential Drug Target for Various Diseases

CMAHP (Cytokine-Mediated Auto-Inhibition of HeLa-Platelet Aggregation), also known as CSAH (Cytokine-Sensitive Auto-Inhibition of HeLa-Platelet Aggregation), is a protein that is expressed in various cell types, including hematopoietic stem cells, immune cells, and cancer cells. It is a key regulator of platelet aggregation, which is the process by which platelets stick together to form blood clots.

CMAHP has been identified as a potential drug target for various diseases, including cancer, cardiovascular disease, and neurological disorders. Its role in platelet aggregation makes it an attractive target for therapies that aim to prevent or alleviate platelet-related complications.

One of the key advantages of CMAHP as a drug target is its broad spectrum. It is highly expressed in various cell types, which means that targeting it may be effective in treating a wide range of conditions. Additionally, CMAHP is involved in multiple signaling pathways, which makes it a potential candidate for targeting with small molecules or other types of therapies.

CMAHP functions as a negative regulator of platelet aggregation. It inhibits the aggregation of platelets by regulating the activity of several enzymes involved in the platelet aggregation pathway. These enzymes include the factors that promote aggregation, such as the cytokine GFAP, and the protein SM- actinin.

In addition to its role in platelet aggregation, CMAHP has also been shown to play a key role in the regulation of cellular processes that are important for overall cellular health. For example, it has been shown to be involved in the regulation of cell cycle progression. , apoptosis, and angiogenesis.

CMAHP is also a good candidate for a drug because it is a protein that can be targeted with small molecules. This is a major advantage, as many diseases are currently treated with drugs that are not effective in targeting proteins. Additionally, because CMAHP is involved in multiple signaling pathways, it is possible that targeting it with small molecules may have unintended consequences that could be harmful.

CMAHP has been shown to be involved in the regulation of platelet aggregation in various models of cancer. For example, studies have shown that inhibiting CMAHP can significantly reduce the formation of blood clots in cancer cells. This suggests that targeting CMAHP may be an effective way to treat cancer by inhibiting platelet-related complications.

In addition to its potential use in cancer, CMAHP has also been identified as a potential drug target for other conditions, including cardiovascular disease and neurological disorders. For example, studies have shown that CMAHP is involved in the regulation of platelet aggregation in the development of atherosclerosis, which is a leading cause of cardiovascular disease. Additionally, CMAHP has been shown to be involved in the regulation of platelet aggregation in the development of neurodegenerative disorders.

Overall, CMAHP is a protein that has broad potential as a drug target. Its role in platelet aggregation makes it an attractive target for therapies that aim to prevent or alleviate platelet-related complications. Additionally, its broad spectrum and the potential for targeting it with small molecules makes it a promising candidate for treatment of a wide range of conditions. Further research is needed to fully understand the role of CMAHP in cellular processes and its potential as a drug target.

Protein Name: Cytidine Monophospho-N-acetylneuraminic Acid Hydroxylase, Pseudogene

Functions: Sialic acids are components of carbohydrate chains of glycoconjugates and are involved in cell-cell recognition and cell-pathogen interactions. That protein has no CMP-N-acetylneuraminate monooxygenase activity and is not able to convert CMP-N-acetylneuraminic acid (CMP-Neu5Ac) into its hydroxylated derivative CMP-N-glycolylneuraminic acid (CMP-Neu5Gc), a sialic acid abundantly expressed at the surface of many cells in vertebrates (PubMed:9624188). However, it may play a role in Wnt signaling (PubMed:19890979)

More Common Targets